A Study to Assess the Efficacy and Safety of MSTT1041A in Participants With Uncontrolled Severe Asthma

NCT ID: NCT02918019

Last Updated: 2022-12-28

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

517 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-09-20

Study Completion Date

2019-07-26

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a Phase IIb, randomized, placebo-controlled, double-blind, multicenter, multi-arm study which will evaluate efficacy, safety, and pharmacokinetic of MSTT1041A compared with placebo as add-on therapy in participants with severe, uncontrolled asthma who are receiving medium- or high-dose inhaled corticosteroid (ICS) therapy and at least one of the following additional controller medications: long-acting beta-agonists (LABA), leukotriene modifier (LTM), long-acting muscarinic antagonist (LAMA), or long-acting theophylline preparation. The total duration of this study for each participant is approximately 70 weeks including screening, run-in, treatment, and follow-up.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Asthma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

MSTT1041A 210 mg

Participants will receive MSTT1041A 210 milligrams (mg), subcutaneously every 4 weeks from randomization through Week 50.

Group Type EXPERIMENTAL

MSTT1041A

Intervention Type DRUG

MSTT1041A will be administered as subcutaneous injections.

MSTT1041A 490 mg

Participants will receive MSTT1041A 490 mg, subcutaneously every 4 weeks from randomization through Week 50.

Group Type EXPERIMENTAL

MSTT1041A

Intervention Type DRUG

MSTT1041A will be administered as subcutaneous injections.

MSTT1041A 70 mg

Participants will receive MSTT1041A 70 mg, subcutaneously every 4 weeks from randomization through Week 50.

Group Type EXPERIMENTAL

MSTT1041A

Intervention Type DRUG

MSTT1041A will be administered as subcutaneous injections.

Placebo

Participants will receive placebo matched with MSTT1041A, subcutaneously every 4 weeks from randomization through Week 50.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo matched with MSTT1041A.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MSTT1041A

MSTT1041A will be administered as subcutaneous injections.

Intervention Type DRUG

Placebo

Placebo matched with MSTT1041A.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

RO7187807

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Body mass index (BMI) of 18 to 38 kilogram/square meter (kg/m\^2) and weight \>= 40 kg at screening
* Documented physician-diagnosed asthma
* On high dose inhaled corticosteroid (ICS) therapy plus at least one additional allowed controller medication
* Forced expiratory volume in 1 second (FEV1) of 40% to 80% of predicted
* Evidence of uncontrolled asthma
* Use of contraceptive measures

Exclusion Criteria

* Diagnosis of mimics of asthma
* Diagnosis of occupational asthma, aspirin-sensitive asthma, asthma chronic obstructive pulmonary disease overlap syndrome, or bronchiolitis, as determined by the investigator
* Pregnant or lactating, or intending to become pregnant during the study or within 20 weeks after the last dose of MSTT1041A
* Recent history of smoking
* History or evidence of substance abuse that would pose a risk to participants safety, interfere with the conduct of the study, have an impact on the study results
* Asthma exacerbation within 4 weeks prior to screening
* Intubation for respiratory failure due to asthma within 12 months prior to screening
* Comorbid conditions that may interfere with evaluation of investigational medicinal product
* Known sensitivity to any of the active substances or their excipients to be administered during dosing
* Positive pregnancy test
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hoffmann-La Roche

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Clinical Trials

Role: STUDY_DIRECTOR

Hoffmann-La Roche

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Alabama Allergy & Asthma

Birmingham, Alabama, United States

Site Status

Del Sol Research Management

Tucson, Arizona, United States

Site Status

Kern Allergy Med Clinic, Inc.

Bakersfield, California, United States

Site Status

Allergy & Asthma Care Center of Southern California

Long Beach, California, United States

Site Status

CA Allergy & Asthma Med Grp; Medical Group, Inc.

Los Angeles, California, United States

Site Status

Jonathan Corren MD, Inc.

Los Angeles, California, United States

Site Status

Office of Robert N Wolfe MD

Los Angeles, California, United States

Site Status

Advances in Medicine

Rancho Mirage, California, United States

Site Status

Allergy & Asthma Consultants

Redwood City, California, United States

Site Status

Bensch Research Associates

Stockton, California, United States

Site Status

Allergy and Asthma Clinical Research, Inc.

Walnut Creek, California, United States

Site Status

IMMUNOe Research Centers

Centennial, Colorado, United States

Site Status

Asthma & Allergy; Associates, P.C.

Colorado Springs, Colorado, United States

Site Status

Western States Clinical Research, Inc

Wheat Ridge, Colorado, United States

Site Status

Yale University School Of Medicine

New Haven, Connecticut, United States

Site Status

Emerald Coast Research Associates

Panama City, Florida, United States

Site Status

Florida Premier Research Institute

Winter Park, Florida, United States

Site Status

Atlanta Allergy & Asth Clin PC

Stockbridge, Georgia, United States

Site Status

Asthma & Allergy of Idaho

Twin Falls, Idaho, United States

Site Status

Asthma, Allergy & Sinus Center

Baltimore, Maryland, United States

Site Status

Chesapeake Clinical Research Inc - CRN

Baltimore, Maryland, United States

Site Status

Genesis Clinical Research & Consulting, LLC

Fall River, Massachusetts, United States

Site Status

Infinity Medical Research Inc

North Dartmouth, Massachusetts, United States

Site Status

Midwest Clinical Research LLC

St Louis, Missouri, United States

Site Status

The Allergy and Asthma Center

Bellevue, Nebraska, United States

Site Status

Montefiore Medical Center

The Bronx, New York, United States

Site Status

American Health Research Inc.

Charlotte, North Carolina, United States

Site Status

Allergy & Respiratory Center

Canton, Ohio, United States

Site Status

Integrity People Services Research Company

Oklahoma City, Oklahoma, United States

Site Status

Vital Prospects Clin Res Pc

Tulsa, Oklahoma, United States

Site Status

Temple University Hospital

Philadelphia, Pennsylvania, United States

Site Status

Asthma & Allergy Physicians of Rhode Island Clinical Research Institute (AAPRI CRI)

Warwick, Rhode Island, United States

Site Status

Spartanburg Medical Research

Spartanburg, South Carolina, United States

Site Status

Clinical Research Solutions PC

Knoxville, Tennessee, United States

Site Status

Meharry Medical College; Clinical Trials Office

Nashville, Tennessee, United States

Site Status

TTS Research

Boerne, Texas, United States

Site Status

Elliot J. Ginchansky, MD, PA

Dallas, Texas, United States

Site Status

Pioneer Research Solutions

Houston, Texas, United States

Site Status

Metroplex Pulmonology & Sleep Center

McKinney, Texas, United States

Site Status

Allergy & Asthma Research Center

San Antonio, Texas, United States

Site Status

Allergy Associates of Utah

Murray, Utah, United States

Site Status

Commonwealth Clinical Research Specialists

Richmond, Virginia, United States

Site Status

Washington Univ School of Med

Seattle, Washington, United States

Site Status

Fundacion Cidea

Buenos Aires, , Argentina

Site Status

INAER

Buenos Aires, , Argentina

Site Status

Fundacion Scherbovsky

Mendoza, , Argentina

Site Status

INSARES

Mendoza, Mendoza City, , Argentina

Site Status

Centro Respiratorio Quilmes

Quilmes, , Argentina

Site Status

Instituto Especialidades de la Salud Rosario

Rosario, , Argentina

Site Status

Instituto de Diagnóstico ABC; Servicio de Investigación de Patologías Alérgicas

Rosario, , Argentina

Site Status

Centro Modelo de Cardiologia

San Miguel de Tucumán, , Argentina

Site Status

Investigaciones en Patologias Respiratorias

San Miguel de Tucumán, , Argentina

Site Status

CEMER Centro Medico de Enfermedades Respiratorias

Vicente López, , Argentina

Site Status

Cliniques Universitaires St-Luc

Brussels, , Belgium

Site Status

Private Practice Dr Jean Benoit Martinot

Erpent, , Belgium

Site Status

Military Medical Academy HBAT

Pleven, , Bulgaria

Site Status

SHATPPD Dr. Dimitar Gramatikov, Ruse Ltd.

Rousse, , Bulgaria

Site Status

Medical Centre Mladost Med 1 EOOD

Sofia, , Bulgaria

Site Status

First MHAT; Clinic of Neurology

Sofia, , Bulgaria

Site Status

Fifth MHAT - Sofia EAD

Sofia, , Bulgaria

Site Status

National Multiprofile Hospital Tsar Boris III

Sofia, , Bulgaria

Site Status

Specialised Hospital for Active Treatment of Pulmonary Deseases "Sv. Sofia", Third Clinic for Non-Sp

Sofia, , Bulgaria

Site Status

Uni. Multiprofile Hosp. for Active Treatment-Aleksandrovska

Sofia, , Bulgaria

Site Status

Medical Center N.I. Pirogov EOOD

Sofia, , Bulgaria

Site Status

Alitera - Med - Medical Center EOOD

Sofia, , Bulgaria

Site Status

Medical Center "Nov Rehabilitatsionen Tsentar", EOOD

Stara Zagora, , Bulgaria

Site Status

Medical Center Tara OOD

Veliko Tarnovo, , Bulgaria

Site Status

Aggarwal and Associates

Brampton, Ontario, Canada

Site Status

Cheema Research

Mississauga, Ontario, Canada

Site Status

Inspiration Research

Toronto, Ontario, Canada

Site Status

Anil Dhar Professional Medicine Corporation

Windsor, Ontario, Canada

Site Status

C.I.C. Mauricie

Trois-Rivières, Quebec, Canada

Site Status

MediTrial s.r.o.

Jindřichův Hradec, , Czechia

Site Status

EUC Klinika Ostrava a.s.

Ostrava-Poruba, , Czechia

Site Status

Ordinace pro tuberkulozu a respiracni nemoci

Strakonice, , Czechia

Site Status

KASMED s.r.o.

Tábor, , Czechia

Site Status

Alergologie Teplice, s.r.o.

Teplice, , Czechia

Site Status

Pneumologisches Forschungsinstitut Hohegeest

Geesthacht, , Germany

Site Status

POIS Leipzig Gbr

Leipzig, , Germany

Site Status

Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Medizinische Klinik, Pneumologie

Mainz, , Germany

Site Status

Universitatsklinikum Munster

Münster, , Germany

Site Status

Greenlane Clinical Centre

Auckland, , New Zealand

Site Status

Medical Research Institute of New Zealand

Wellington, , New Zealand

Site Status

Clinica Internacional

Lima, , Peru

Site Status

Abk Reuma Srl- Medicentro

Lima, , Peru

Site Status

Clinica Ricardo Palma; THORAX

Lima, , Peru

Site Status

Instituto Peruano de Investigacion en Ciencias Medicas

Lima, , Peru

Site Status

Clinica San Borja

Lima, , Peru

Site Status

Hospital Santa Rosa Piura

Piura, , Peru

Site Status

Centrum Medycyny Oddechowej Robert M. Mróz

Bialystok, , Poland

Site Status

Centrum Medyczne ALL-MED

Krakow, , Poland

Site Status

Malopolskie Centrum Alergologii

Krakow, , Poland

Site Status

Niepubliczny Zaklad Opieki Zdrowotnej Centrum Medyczne ProMiMed sp z o.o. sp.k.

Krakow, , Poland

Site Status

SPZOZ Uniwersytecki Szpital Kliniczny nr 1 im. Norberta Barlickiego Uniwersytetu Medycznego w Lodzi

Lodz, , Poland

Site Status

Specjalistyczna Poradnia Pulmonologiczna

Ostrów Wielkopolski, , Poland

Site Status

Przedsiebiorstwo Podmiotu Leczniczego Poradnie Specjalistyczne MAGMED

Radom, , Poland

Site Status

ALERGO-MED Specjalistyczna Przychodnia Lekarska Sp. z o. o

Tarnów, , Poland

Site Status

Ewa Pisarczyk-Bogacka Specjalistyczna Praktyka Lekarska

Wroclaw, , Poland

Site Status

NZOZ Lekarze Specjaliści J. Małolepszy i Partnerzy

Wroclaw, , Poland

Site Status

Theramed SRL

Brasov, , Romania

Site Status

Spitalul Clinic de Pneumoftiziologie Leon Daniello Cluj-Napoca, Sectia Clinica Pneumologie I

Cluj-Napoca, , Romania

Site Status

Spitalul Clinic de Boli Infectioase si Pneumoftiziologie Victor Babes Craiova

Craiova, , Romania

Site Status

Fundatia CardioPrevent

Timișoara, , Romania

Site Status

Dr. Victor Babes Pneumology and Infectious Diseases Clinical Hospital

Timișoara, , Romania

Site Status

Clinical Emergency Hospital n.a.N.V. Soloviev

Yaroslavl, Moscow Oblast, Russia

Site Status

LLC - ABC Medicina

Moscow, Sankt-Peterburg, Russia

Site Status

City Hospital #5

Barnaul, , Russia

Site Status

Municipal Healthcare Institution City Clinical Hospital #3 named after M.A. Podgorbunskogo

Kemerovo, , Russia

Site Status

I.M. Sechenov Moscow State Medical University the Ministry of Health and Social Development of RF

Moscow, , Russia

Site Status

Novosibirsk Municipal Clinical Hospital For Emergency Medicine #2

Novosibirsk, , Russia

Site Status

City Clinical Hospital #2

Novosibirsk, , Russia

Site Status

Ryazan State Medical University Named after I.P.Pavlov

Ryazan, , Russia

Site Status

Clinic Reavita LLC

Saint Petersburg, , Russia

Site Status

SHI Ctr Occupational Pathology

Saint Petersburg, , Russia

Site Status

St. Petersburg State Medical University n.a. I.P. Pavlov

Saint Petersburg, , Russia

Site Status

City Hospital #40 of Resort Administrative District

Saint Petersburg, , Russia

Site Status

Siberian State Medical University

Tomsk, , Russia

Site Status

Tiervalei Trial Centre

Cape Town, , South Africa

Site Status

University of Cape Town Lung Institute; Lung Clinical Research

Cape Town, , South Africa

Site Status

St Augustines Hospital; Infectoilogy

Durban, , South Africa

Site Status

Vawda Z.Fa Practice

Durban, , South Africa

Site Status

Aliwal Shoal Medical Center

eMkhomazi, , South Africa

Site Status

Seoul National University Hospital

Seoul, , South Korea

Site Status

Severance Hospital, Yonsei University Health System

Seoul, , South Korea

Site Status

Asan Medical Center

Seoul, , South Korea

Site Status

Regional Municipal Institution Chernivtsi Regional Clinical Hospital

Chernivtsi, Chernihiv Governorate, Ukraine

Site Status

Municipal institution; City hospital #1; Department of Therapy

Zaporizhzhia, Kherson Governorate, Ukraine

Site Status

Kyiv City Tuberculosis Hospital #1; Department of Differential Diagnosis of Lung Diseases

Kyiv, KIEV Governorate, Ukraine

Site Status

Public Institution City Clinical Hospital # 6 of Dnipropetrovsk Regional Board

Dnipro, , Ukraine

Site Status

Ukrainian State Institute of Medical and Social Problems of Disability

Dnipropetrovsk, , Ukraine

Site Status

Regional Phthisiology and Pulmonology Center

Ivano-Frankivsk, , Ukraine

Site Status

SI Institute of Therapy n.a. L.T. Mala of National Academy of Medical Sciences of Ukraine

Kharkiv, , Ukraine

Site Status

SI National Institute of Phthisiology and Pulmonology n.a. F.G.Yanovskyi under NAMS of Ukraine

Kyiv, , Ukraine

Site Status

Municipal Institution of Kyiv Regional Council Kyiv Regional Clinical Hospital

Kyiv, , Ukraine

Site Status

Kyiv City Clinical Hospital #8

Kyiv, , Ukraine

Site Status

City Hospital #1

Mykolaiv, , Ukraine

Site Status

Municipal Institution Odesa Regional Clinical Hospital

Odesa, , Ukraine

Site Status

Small Business Private Enterprise Medical Centre Pulse

Vinnytsia, , Ukraine

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Argentina Belgium Bulgaria Canada Czechia Germany New Zealand Peru Poland Romania Russia South Africa South Korea Ukraine

References

Explore related publications, articles, or registry entries linked to this study.

Yin Z, Zhou Y, Turnquist HR, Liu Q. Neuro-epithelial-ILC2 crosstalk in barrier tissues. Trends Immunol. 2022 Nov;43(11):901-916. doi: 10.1016/j.it.2022.09.006. Epub 2022 Oct 14.

Reference Type DERIVED
PMID: 36253275 (View on PubMed)

Kelsen SG, Agache IO, Soong W, Israel E, Chupp GL, Cheung DS, Theess W, Yang X, Staton TL, Choy DF, Fong A, Dash A, Dolton M, Pappu R, Brightling CE. Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: A randomized clinical trial. J Allergy Clin Immunol. 2021 Sep;148(3):790-798. doi: 10.1016/j.jaci.2021.03.044. Epub 2021 Apr 16.

Reference Type DERIVED
PMID: 33872652 (View on PubMed)

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2016-001549-13

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

GB39242

Identifier Type: -

Identifier Source: org_study_id